Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2012 Apr 18;4(4):CD008989.
doi: 10.1002/14651858.CD008989.pub2.

Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease

Charlotta Karner  1 , Christopher J Cates
Affiliations
Meta-Analysis

Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease

Charlotta Karner et al. Cochrane Database Syst Rev. .

Update in

Abstract

Background: Long-acting bronchodilators comprising long-acting beta(2)-agonists and the anticholinergic agent tiotropium are commonly used for managing persistent symptoms of chronic obstructive pulmonary disease. Combining these treatments, which have different mechanisms of action, may be more effective than the individual components. However, the benefits and risks of combining tiotropium and long-acting beta(2)-agonists for the treatment of chronic obstructive pulmonary (COPD) disease are unclear.

Objectives: To assess the relative effects of treatment with tiotropium in addition to long-acting beta(2)-agonist compared to tiotropium or long-acting beta(2)-agonist alone in patients with chronic obstructive pulmonary disease.

Search methods: We searched the Cochrane Airways Group Specialised Register of trials and clinicaltrials.gov up to January 2012.

Selection criteria: We included parallel group, randomised controlled trials of three months or longer comparing treatment with tiotropium in addition to long-acting beta(2)-agonist against tiotropium or long-acting beta(2)-agonist alone for patients with chronic obstructive pulmonary disease.

Data collection and analysis: Two review authors independently assessed trials for inclusion and then extracted data on trial quality and the outcome results. We contacted study authors for additional information. We collected information on adverse effects from the trials.

Main results: Five trials were included in this review, mostly recruiting participants with moderate or severe chronic obstructive pulmonary disease. All of them compared tiotropium in addition to long-acting beta(2)-agonist to tiotropium alone, but only one trial additionally compared a combination of the two types of bronchodilator with long-acting beta(2)-agonist (formoterol) alone. Two studies used the long-acting beta(2)-agonist indacaterol, two used formoterol and one used salmeterol.Compared to tiotropium alone (3263 patients), treatment with tiotropium plus long-acting beta(2)-agonist resulted in a slightly larger improvement in the mean health-related quality of life (St George's Respiratory Questionnaire (SGRQ) MD -1.61; 95% CI -2.93 to -0.29). In the control arm, tiotropium alone, the SGRQ improved by falling 4.5 units from baseline and with both treatments the improvement was a fall of 6.1 units from baseline (on average). High withdrawal rates in the trials increased the uncertainty in this result, and the GRADE assessment for this outcome was therefore moderate. There were no significant differences in the other primary outcomes (hospital admission or mortality).The secondary outcome of pre-bronchodilator FEV(1) showed a small mean increase with the addition of long-acting beta(2)-agonist (MD 0.07 L; 95% CI 0.05 to 0.09) over the control arm, which showed a change from baseline ranging from 0.03 L to 0.13 L on tiotropium alone. None of the other secondary outcomes (exacerbations, symptom scores, serious adverse events, and withdrawals) showed any statistically significant differences between the groups. There were wide confidence intervals around these outcomes and moderate heterogeneity for both exacerbations and withdrawals.The results from the one trial comparing the combination of tiotropium and long-acting beta(2)-agonist to long-acting beta(2)-agonist alone (417 participants) were insufficient to draw firm conclusions for this comparison.

Authors' conclusions: The results from this review indicate a small mean improvement in health-related quality of life for patients on a combination of tiotropium and long-acting beta(2)-agonist compared to tiotropium alone, but it is not clear how clinically important this mean difference may be. Hospital admission and mortality have not been shown to be altered by adding long-acting beta(2)-agonists to tiotropium. There were not enough data to determine the relative efficacy and safety of tiotropium plus long-acting beta(2)-agonist compared to long-acting beta(2)-agonist alone. There were insufficient data to make comparisons between the different long-acting beta(2)-agonists when used in addition to tiotropium.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study flow diagram.
Figure 2
Figure 2
Risk of bias summary: review authors’ judgements about each risk of bias item for each included study.
Figure 3
Figure 3
Forest plot of comparison: 1 LABA plus tiotropium versus tiotropium, outcome: 1.1 Change in quality of life.
Figure 4
Figure 4
Forest plot of comparison: 1 LABA plus tiotropium versus tiotropium, outcome: 1.2 Hospital admission (all cause).
Figure 5
Figure 5
Forest plot of comparison: 1 LABA plus tiotropium versus tiotropium, outcome: 1.3 Hospital admission (exacerbation).
Figure 6
Figure 6
Forest plot of comparison: 1 LABA plus tiotropium versus tiotropium, outcome: 1.4 Mortality (all cause).
See this image and copyright information in PMC

References

References to studies included in this review

    1. Aaron SD, Vandemheen K, Ferguson D, FitzGerald M, Maltais F, Boureau J, et al. The Canadian optimal therapy of COPD trial: Design, organization and patient recruitment. Canadian Respiratory Journal. 2004;11(8):581–5. - PubMed

    2. *

    3. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. [see comment][summary for patients in Ann Intern Med. 2007 Apr 17;146(8):I12. PMID: 17310044] - PubMed
    4. Annals of Internal Medicine. 2007;146(8):545–55. - PubMed
    5. Kaplan A. Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal. 2007;16(4):258–60. - PMC - PubMed
    6. Najafzadeh M, Marra CA, Sadatsafavi M, Aaron SD, Sullivan SD, Vandemheen KL, et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax. 2008;63(11):962–7. - PubMed
    7. Roisman G. Tiotropium in combination with placebo, salmeterol, or fluticasone- salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique. 2007;63(6):390–1. - PubMed
    1. www.novctrd.com. [: CQAB149B2341]
    2. Mahler DA, D’Urzo A, Peckitt C, Lassen C, Kramer B, Filcek S. Combining once-daily bronchodilators In COPD: Indacaterol plus tiotropium versus tiotropium alone. American Journal of Respiratory and Critical Care Medicine. 2011;(issue 183)

    3. * A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate-to-severe chronic obstructive pulmonary disease.

    1. www.novctrd.com. [: CQAB149B2351]
    2. Mahler DA, D’Urzo A, Peckitt C, Lassen C, Kramer B, Filcek S. Combining once-daily bronchodilators In COPD: Indacaterol plus tiotropium versus tiotropium alone. American Journal of Respiratory and Critical Care Medicine. 2011;(issue 183)

    3. * A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate-to-severe chronic obstructive pulmonary disease.

    1. Tashkin D, Varghese S. Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract] Journal of Allergy and Clinical Immunology. 2007;Vol. 119(issue 1 Suppl):S4. [13]
    2. Tashkin D, Varghese S. The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12-week, multicenter, double-blind, placebo-controlled, trial. Chest. 2007;Vol. 132(issue 4):529a.
    3. Tashkin DP. Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; Toronto. May 16-21, 2008; 2008. p. A647. [#F5]

    4. *

    5. Tashkin DP, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2009;6(1):17–25. - PubMed
    6. Tashkin DP, Pearle JL, Varghese S. Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract] Chest. 2008;Vol. 134(issue 4):103002s.
    1. Arievich H, Potena A, Fonay K, Vogelmeier CF, Overend T, Smith J, et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract] European Respiratory Journal. 2006;Vol. 28(issue Suppl 50):440s. [P2514]
    2. www.novctrd.com. [: CFOR258F2402]

    3. *

    4. Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respiratory Medicine. 2008;102(11):1511–20. - PubMed
    5. Vogelmeier CF, Harari SA, Fonay K, Beier J, Overend T, Till D, et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract] European Respiratory Journal. 2006;Vol. 28(issue Suppl 50):429s. [P2506]

    6. Novartis. A randomized, multi-center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable Chronic Obstructive Pulmonary Disease.

References to studies excluded from this review

    1. *

    2. Bateman ED, Hodder R, Miravitlles M, Lee A, Towse L, Serby C. A comparative trial of tiotropium, salmeterol and placebo: health-related quality of life. European Respiratory Journal. 2001;Vol. 18(issue Suppl 33):26s.

    1. *

    2. Brusasco V, Menjoge SS, Kesten S. Flow and volume responders following treatment with tiotropium and salmeterol in patients with COPD [abstract]. American Thoracic Society 99th International Conference; 2003; B024 Poster 420.

    1. *

    2. Di Marco F, Carlucci P, Ccarlucci P, Verga M, Mondoni M, Pistone A, et al. A single dose of formoterol (FOR) and tiotropium (TIO) reduce hyperinflation in COPD patients [Abstract] European Respiratory Journal. 2003;Vol. 22(issue Suppl 45) Abstract No: [P1844]

    1. *

    2. Fujimoto K, Komatsu Y, Kanda S, Itou M, Yoshikawa S, Yasuo M, et al. Comparison of clinical efficacy of tiotropium and salmeterol for pulmonary function, air-trapping, exercise capacity, and HRQO in COPD [Abstract] Respirology. 2007;Vol. 12(issue Suppl 4):A164.

    1. *

    2. Gross NJ, Paulson D, Kennedy D, Korducki L, Kesten S. A comparison of maintenance tiotropium and salmeterol on arterial blood gas tensions in patients with COPD [Abstract] Respiratory Care. 2003;Vol. 48(issue 11):1081.

Additional references

    1. Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan MMK, et al. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2006;(Issue 3) [DOI: 10.1002/14651858.CD001104.pub2] - PMC - PubMed
    1. Barr RG, Bourbeau J, Camargo Carlos A. Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2005;(Issue 2) [DOI: 10.1002/14651858.CD002876.pub2] - PMC - PubMed
    1. Beeh KM, Beier J. Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases. Advances in Therapy. 2009 Jul 18;Vol. 26(issue 7):691–9. 2009. [0741–238X: (Print)] - PubMed
    1. Beier J, Beeh KM. Long-acting beta-adrenoceptor agonists in the management of COPD: focus on indacaterol. International Journal of Chronic Obstructive Pulmonary Disease. 2011 Aug 05;Vol. 6:237–43. 2011. [1178–2005: (Electronic)] - PMC - PubMed
    1. Berger WE, Nadel JA. Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease. Respiratory Medicine. 2008;102(2):173–88. [0954–6111: (Print)] - PubMed

Publication types

MeSH terms